Chest Pain and ST-Segment Elevation Authors: Paul J. Pecorin, Joshua Dein, Daneyal Syed, Matthew Demetrious, Christopher W. Seder, Marta Batus, Fareed Collado, Tochukwu Okwuosa Published: 2024 ABSTRACT Primary cardiac angiosarcomas are rare malignant tumors that can cause chest pain and heart failure symptoms. They can be diagnosed using multimodality imaging, primarily echocardiogram, with formal diagnosis requiring biopsy. A 56-year-old man with history of hypertension and dyslipidemia presented with acute crushing chest pain and shortness of breath. Electrocardiogram showed diffuse ST-segment elevations. Urgent coronary angiography revealed no significant coronary disease but found delayed contrast filling from the left coronary artery to a structure overlying the right atrium with further work-up revealing primary cardiac angiosarcoma. This case represents a unique scenario in which primary cardiac angiosarcoma was discovered from coronary angiography. Clinicians should prioritize and rule out life-threatening emergencies but should recognize the utility of angiography in elucidating other etiologies of chest pain (eg, angiosarcoma). Finally, early screening for metastatic disease should be completed to identify alternative potential biopsy targets. History of Presentation A 56-year-old man presented to the emergency department with acute, crushing, nonexertional, substernal chest pain and dyspnea at rest. He was hemodynamically stable on 2 L of supplemental oxygen. Electrocardiogram showed diffuse ST-segment elevations, most prominent in inferior leads. Chest radiograph was unremarkable. Laboratory work-up was significant for high-sensitivity troponin of 4.6 ng/L, venous pH of 7.411, lactic acid of 2.9 mmol/L, and leukocyte count of 11.8 × 109/L. He was taken for an urgent coronary angiogram which showed normal coronary arteries but demonstrated delayed contrast filling from the left coronary artery to an unknown structure overlying the right atrium (Figure 1). Transthoracic echocardiogram (TTE) showed a 3.8- × 3.7-cm mass abutting the right atrial cavity (Figure 2), which was not present on his prior echocardiogram. Additionally, there was a small pericardial effusion without evidence of hemodynamic compromise. Left ventricular ejection fraction was 55% to 60%, and diastolic function was normal.Learning Objectives•To recognize coronary angiogram as an unusual mechanism of identifying primary cardiac malignancies, especially vascular tumors such as cardiac angiosarcoma.•To recognize the importance of early metastatic screening for cardiac angiosarcoma to locate areas for safer biopsy and diagnosis.Figure 1Coronary AngiogramAngiography of the left coronary artery demonstrates delayed contrast filling from the left coronary arteries to a vascular structure overlying the right atrium highlighted by the arrows.Figure 2Transthoracic Echocardiography(A) Apical 4-chamber view demonstrates a mass abutting the right atrium with a small pericardial effusion. (B) Subcostal view redemonstrates a mass measured as 3.69 × 3.81 cm abutting the right atrium. Learning Objectives •To recognize coronary angiogram as an unusual mechanism of identifying primary cardiac malignancies, especially vascular tumors such as cardiac angiosarcoma.•To recognize the importance of early metastatic screening for cardiac angiosarcoma to locate areas for safer biopsy and diagnosis. •To recognize coronary angiogram as an unusual mechanism of identifying primary cardiac malignancies, especially vascular tumors such as cardiac angiosarcoma. To recognize coronary angiogram as an unusual mechanism of identifying primary cardiac malignancies, especially vascular tumors such as cardiac angiosarcoma. •To recognize the importance of early metastatic screening for cardiac angiosarcoma to locate areas for safer biopsy and diagnosis. To recognize the importance of early metastatic screening for cardiac angiosarcoma to locate areas for safer biopsy and diagnosis. Coronary Angiogram Angiography of the left coronary artery demonstrates delayed contrast filling from the left coronary arteries to a vascular structure overlying the right atrium highlighted by the arrows. Transthoracic Echocardiography (A) Apical 4-chamber view demonstrates a mass abutting the right atrium with a small pericardial effusion. (B) Subcostal view redemonstrates a mass measured as 3.69 × 3.81 cm abutting the right atrium. Visual Summary. Timeline of the CaseCKD = chronic kidney disease; CT = computed tomography; EF = ejection fraction; EKG = electrocardiogram; HTN = hypertension; IVC = inferior vena cava; LHC = left heart catheterization; LV = left ventricular; MRI = magnetic resonance imaging; SVC = superior vena cava; TTE = transthoracic echocardiogram; VATS = video-assisted thoracoscopic surgery. Visual Summary. Timeline of the Case CKD = chronic kidney disease; CT = computed tomography; EF = ejection fraction; EKG = electrocardiogram; HTN = hypertension; IVC = inferior vena cava; LHC = left heart catheterization; LV = left ventricular; MRI = magnetic resonance imaging; SVC = superior vena cava; TTE = transthoracic echocardiogram; VATS = video-assisted thoracoscopic surgery. Past Medical History His past medical history was significant for chronic kidney disease, hypertension, dyslipidemia, limited cutaneous systemic sclerosis on immunosuppression, and obstructive lung disease. A TTE performed to evaluate dyspnea 2 years prior revealed a left ventricular ejection fraction of 55% to 60% with normal diastolic function and pulmonary artery systolic pressure of 31 mm Hg without evidence of a cardiac mass. Differential Diagnosis Initially, differential diagnosis included acute coronary syndrome, heart failure, pericarditis, pulmonary embolism, and exacerbation of obstructive lung disease. After identification of the vascular mass, differential diagnosis included primary cardiac angiosarcoma, lymphoma, metastatic disease, and cardiac myxoma. Investigation The patient’s chest pain, mediastinal mass, and dyspnea were further investigated with computed tomography angiography (CTA) of the chest and cardiac magnetic resonance (cMRI). CTA was negative for pulmonary embolism but revealed a lobulated mass posterosuperior to the right atrium, likely extending into the right atrial appendage causing extrinsic mass effect on the atria, superior vena cava, and right inferior pulmonary vein. Additionally, a 7-mm nodule was present in the left upper lobe of the lung (Figure 3). cMRI demonstrated a 4.9- × 6.5-cm solid, heterogenous mass in the pericardial space in close association with the right atrium. The mass abutted the superior vena cava and extended along the superior and posterior walls of the right atrium. There was mass effect on the interatrial septum, distal superior vena cava, and right inferior pulmonary vein. Tissue characterization suggested a solid vascular mass with a heterogenous central area of lipids or necrotic material and avid gadolinium uptake (Figure 4).Figure 3Computed Tomography Angiography of ChestContrast-enhanced computed tomography reveals a lobulated mass posterosuperior to the right atrium with extrinsic mass effect on the right atria, superior vena cava, and right inferior pulmonary vein highlighted by the arrow.Figure 4Cardiovascular Magnetic Resonance With Cine Steady-State Free Precession Images(A and B) Images confirm the presence of a mass in the pericardial space abutting the right atrium. (C and D) T1- and T2-weighted imaging shows a heterogenous hyperintense signal intensity of the mass. The mass does not demonstrate contrast uptake on early first-pass perfusion sequences (E), but avidly takes up contrast as contrast moves through the left heart (F). Computed Tomography Angiography of Chest Contrast-enhanced computed tomography reveals a lobulated mass posterosuperior to the right atrium with extrinsic mass effect on the right atria, superior vena cava, and right inferior pulmonary vein highlighted by the arrow. Cardiovascular Magnetic Resonance With Cine Steady-State Free Precession Images (A and B) Images confirm the presence of a mass in the pericardial space abutting the right atrium. (C and D) T1- and T2-weighted imaging shows a heterogenous hyperintense signal intensity of the mass. The mass does not demonstrate contrast uptake on early first-pass perfusion sequences (E), but avidly takes up contrast as contrast moves through the left heart (F). The next steps in diagnostic evaluation were discussed with cardiothoracic surgery, including the high-risk of biopsying the cardiac mass itself. As a result, video-assisted thoracoscopic surgery with left upper lobe resection was performed with biopsy of the left lung nodule seen on the CTA. The pathology showed a vascular lesion most consistent with metastatic angiosarcoma (Figure 5). Additional staging scans showed no evidence of additional metastatic disease.Figure 5Pathology of Left Upper Lobe Lung Nodule(A) H&E (4× magnification): haphazardly arranged spindle cell proliferation with an ill-defined border and irregular lumens (right), adjacent to normal lung parenchyma (left). (B) H&E (20× Magnification): spindle cell neoplasm with irregular slit-like spaces, highlighting the neoplastic process of the endothelial cells attempting to form vessels but in a disorganized manner. (C) H&E (40× magnification): spindle cell neoplasm with irregular slit-like spaces and adjacent hemosiderin-laden macrophages from red blood cell degradation and phagocytosis. (D) CD31 immunohistochemistry (20× magnification): positive membranous staining of the neoplastic endothelial cells. (E) CD34 immunohistochemistry (20× magnification): positive membranous staining of the neoplastic endothelial cells, highlighting neoangiogenesis, surrounding a nonneoplastic arteriovenous bundle. (F) FLI-1 immunohistochemistry (20× magnification): positive nuclear staining of the neoplastic cells demonstrating mutation of the proto-oncogene involved in tumorigenesis, surrounding a non-neoplastic arteriovenous bundle. (G) CAMTA1 immunohistochemistry (40× magnification): negative staining of all cells, suggesting that this is not an epithelioid hemangioendothelioma. CAMTA1 = Calmodulin Binding Transcription Activator 1; CD = cluster of differentiation; FLI-1 = Friend leukemia integration 1; H&E = hematoxylin and eosin stain. Pathology of Left Upper Lobe Lung Nodule (A) H&E (4× magnification): haphazardly arranged spindle cell proliferation with an ill-defined border and irregular lumens (right), adjacent to normal lung parenchyma (left). (B) H&E (20× Magnification): spindle cell neoplasm with irregular slit-like spaces, highlighting the neoplastic process of the endothelial cells attempting to form vessels but in a disorganized manner. (C) H&E (40× magnification): spindle cell neoplasm with irregular slit-like spaces and adjacent hemosiderin-laden macrophages from red blood cell degradation and phagocytosis. (D) CD31 immunohistochemistry (20× magnification): positive membranous staining of the neoplastic endothelial cells. (E) CD34 immunohistochemistry (20× magnification): positive membranous staining of the neoplastic endothelial cells, highlighting neoangiogenesis, surrounding a nonneoplastic arteriovenous bundle. (F) FLI-1 immunohistochemistry (20× magnification): positive nuclear staining of the neoplastic cells demonstrating mutation of the proto-oncogene involved in tumorigenesis, surrounding a non-neoplastic arteriovenous bundle. (G) CAMTA1 immunohistochemistry (40× magnification): negative staining of all cells, suggesting that this is not an epithelioid hemangioendothelioma. CAMTA1 = Calmodulin Binding Transcription Activator 1; CD = cluster of differentiation; FLI-1 = Friend leukemia integration 1; H&E = hematoxylin and eosin stain. Management After the coronary angiogram, the patient was diagnosed with pericarditis and managed with colchicine and opioids for pain control. He underwent video-assisted thoracoscopic surgery with left upper lobe resection for tissue diagnosis. He was then discharged with adequate pain control and plans to follow-up with the oncology outpatient. Outcome/Follow-Up The patient was discharged with outpatient oncology and cardiothoracic surgery follow-up. He has completed 3 cycles of gemcitabine and docetaxel with plans for restaging with cycle 4 and subsequent consideration for surgical excision of the mass and/or radiation therapy. Discussion Cardiac masses can be broadly classified into benign and malignant primary tumors, metastases, or other etiologies including thrombi and infections. Metastases are more common than primary tumors, the latter of which have an incidence of 1.34 to 30 per 100,000 people per year. Of these, about 20% are malignant and include angiosarcoma, rhabdomyosarcoma, and mesothelioma, with angiosarcoma being the most common. Primary cardiac sarcomas are often diagnosed in younger adults, with a mean age of 46 years at diagnosis, and can be associated with prior chest radiation therapy. They are generally associated with a poor prognosis with median survival of 6 to 12 months at time of diagnosis.1 This is mainly because of delayed presentation, with most patients having evidence of metastatic disease on initial presentation. The most common site of metastatic primary cardiac angiosarcoma is the lungs as was seen in this patient.2 Patients often present with vague symptoms that can mimic pathologies more common than primary cardiac angiosarcoma. The resultant misdiagnosis can be associated with a higher risk of disease progression, metastasis, and poorer overall prognosis. Numerous cases have highlighted these nonspecific symptoms, including patients presenting with fever, dyspnea, cough, or fatigue.3 One review reported that around 46% of patients diagnosed with cardiac angiosarcoma originally presented with a chief complaint of chronic chest pain.4 Unfortunately, by the time symptoms become severe enough for patients to seek medical care, there may already be myocardial or pericardial involvement, pericardial effusion with or without tamponade, valvular disease, or signs of heart failure.5 Multimodality imaging assists in the diagnosis of cardiac angiosarcomas. Most experts consider echocardiography to be the most useful modality, with transesophageal echocardiography demonstrating upward of 97% sensitivity in its diagnosis.6 Furthermore, echocardiography can help assess tumor characteristics to assist in risk stratification and therapeutic planning, including tumor size, location, and its effect on cardiac functioning.7 Other imaging modalities, including computed tomography and cMRI, can further characterize the lesion and investigate metastases. Biopsy of the mass is ultimately required to determine official diagnosis, which presents unique challenges given the location of these masses. This case represents a unique presentation in which cardiac angiosarcoma was first discovered during a coronary angiogram. Given the patient’s significant chest pain in conjunction with ST-segment elevations and age, ruling out acute ST-segment elevation myocardial infarction was prioritized and additional imaging and work-up were deferred to postcatheterization. To our knowledge, there are no documented cases in the literature where a cardiac tumor was initially discovered in this way. There is one case in which cardiac catheterization demonstrated neovascularization of a right atrial mass that was visualized on TTE.8 The authors highlighted the importance of neovascularization in distinguishing angiosarcomas and other malignant cardiac tumors from more benign masses (eg, myxomas) and the utility of coronary angiography in making such a distinction. As was the case with the present patient, neovascularization seen on angiography significantly raised the suspicion of a primary cardiac malignant process and helped to expedite the diagnosis of cardiac angiosarcoma. Furthermore, considering the risks associated with cardiac biopsy, this case underscores the importance of comprehensive screening at the initial diagnosis stage. This approach enables the possibility of biopsy of other masses, particularly in cases of metastatic disease, that may offer easier access for the procedure. Early treatment is essential and ideally involves surgical resection. In some patients there may be benefit from neoadjuvant chemotherapy to shrink the tumor and facilitate subsequent surgical resection.2 Conclusions Overall, this case highlights the diagnostic challenges that clinicians face in diagnosing cardiac angiosarcoma, the unique role that coronary angiography can play in its discovery, risk stratification, and therapeutic management, and the utility of early screening for metastatic disease for alternative potential sources of biopsy access. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.